Item 1.01 Entry into a Material Definitive Agreement.

On February 14, 2023, Arch Therapeutics, Inc. (the "Company") entered into an amendment (the "First Notes Amendment") to its outstanding Senior Secured Convertible Promissory Notes issued on July 6, 2022 (the "First Notes") with the holders of the First Notes. Also on February 14, 2023, the Company entered into an amendment (the "Second Notes Amendment" and, together with the First Notes Amendment, the "Amendments") to its outstanding Unsecured Convertible Promissory Notes issued on January 18, 2023 (the "Second Notes") with the holders of the Second Notes. The Amendments amended the First Notes and Second Notes to extend the date of the completion of an uplist to any of the Nasdaq Global Market, Nasdaq Capital Market, New York Stock Exchange or NYSE American (such transaction, an "Uplist Transaction") from February 15, 2023 to March 15, 2023.

As a result of the entry into the First Notes Amendment, the Company's outstanding Series 3B Convertible Promissory Notes (the "Series 3B Notes") were automatically amended to extend the date of completion of an Uplist Transaction from February 15, 2023 to March 15, 2023 pursuant to the terms of the Series 3B Notes.

The preceding descriptions of the Amendments are qualified in their entirety by reference to the copies of the form of First Notes Amendment and the form of Second Notes Amendment filed herewith as Exhibit 10.1 and Exhibit 10.2 to this Current Report on Form 8-K, respectively, which are incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) The following exhibits are being filed herewith:



Exhibit    Description
  10.1     Form of First Notes Amendment.
  10.2     Form of Second Notes Amendment.
  104      Cover Page Interactive Data File (embedded within the Inline XBRL document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses